ENVALITH
東和薬品株式会社 logo

TOWA PHARMACEUTICAL CO., LTD.

4553・Prime Market・Pharmaceuticals

Official website
東和薬品株式会社 logo
TOWA PHARMACEUTICAL CO., LTD.4553

Business

The Towa Pharmaceutical Group is a major domestic manufacturer whose core business is the manufacturing and sale of generic pharmaceuticals (off-patent drugs). In the Domestic Segment, pharmaceuticals manufactured at the company's own plants (Okayama, Yamagata, Osaka) are sold to medical institutions, pharmaceutical wholesalers, agents, etc., while subsidiaries such as Jaydolf Pharma, Daichi Kasei, Green Capsule Pharma, and Sansei Pharmaceutical handle in-group manufacturing. In the Overseas Segment, through Towa Pharma International Holdings, S.L. (Towa INT), the group operates R&D and manufacturing bases in Europe, conducting sales and contract manufacturing business for generic pharmaceuticals across multiple European countries and the United States. Consolidated net sales for FY2026 (ending March 2026) were ¥273,710 million, with Domestic accounting for approximately 79% and Overseas approximately 21%.

Business Model

Domestically, the company leverages economies of scale from mass production at its own factories, aiming to raise unit prices through a list-price strategy and improved sales mix driven by recent expansion of supplementary listed products. Overseas, Towa INT secures earnings through two pillars—European BtoC sales and contract manufacturing (BtoB)—while also generating synergies through intra-group manufacturing outsourcing (e.g., esomeprazole capsules). Continuous new product listings, backed by R&D expenditure of ¥17,943 million, are expanding the product portfolio, with a lineup of 316 active ingredients and 742 products underpinning the earnings base.

Company Strengths

With the full-scale operation of the third solid dosage form building at the Yamagata Plant starting in October 2025, the combined annual production capacity of the three plants increased from 14.0 billion tablets to 17.5 billion tablets. Furthermore, collaboration agreements with Otsuka Pharmaceutical, Adragos Pharma Kawagoe (approximately 1.5 billion tablets in scale), and Sanwa Kagaku Kenkyusho (approximately 700 million tablets in scale) have established manufacturing capacity beyond the company's own capabilities and a mutual backup system.

Through continuous R&D investment (¥17,943 million in the fiscal year under review), the company held 316 components and 742 items as of December 2025. In FY2025, the company launched 7 components and 14 items, including Rivaruen® LA Patch, Japan's first sustained-release transdermal patch for the treatment of Alzheimer-type dementia, with a further 7 components and 12 items scheduled for supplementary listing in June 2026. This broad product lineup covering a wide range of therapeutic areas contributes to customer retention.

Through Towa INT, the company holds R&D and manufacturing facilities in Europe that comply with Western standards (PIC/S GMP, etc.), and operates existing sales networks across multiple European countries and the United States. Overseas sales reached ¥57,630 million (up 7.0% year on year), and synergies between Japan and Europe have also been realized through intra-group contract manufacturing and joint development. This has diversified revenue sources beyond dependence on the domestic business.

ENVALITH's Perspective

Net income attributable to owners of parent for FY2026 (ending March 2026) fell sharply to ¥5,250 million (down 72.3% year on year). The main cause was the recording of a goodwill impairment loss of ¥14,729 million associated with the deterioration in Sansei Pharmaceutical's performance. On an operating income basis, results were essentially flat at ¥23,102 million (down 0.6% year on year), and while the impairment is a one-time extraordinary loss, the deterioration in Sansei Pharmaceutical's business mix (a downturn in the New Application business) has pushed up the cost of sales ratio in the Domestic Segment, making the recovery of the subsidiary's earnings a key focus going forward. The goodwill balance has been reduced to ¥9,468 million, limiting the risk of further impairment.

Ordinary income for FY2026 (ending March 2026) increased to ¥28,079 million (up 7.4% year on year), but this was significantly boosted by a derivative valuation gain of ¥5,384 million (versus ¥1,259 million in the prior period). As an external factor, the progression of yen depreciation has pushed up yen-denominated sales in the Overseas Segment, while derivative valuation gains/losses can swing significantly depending on exchange rate movements. The assumed exchange rates for FY2027 (ending March 2026) are set at ¥177 per euro and ¥154 per dollar, and continued attention should be paid to how exchange rate trends affect the achievability of the earnings forecast.

The company's forecast for FY2027 (ending March 2026) calls for net sales of ¥304,000 million (up 11.1% year on year), operating income of ¥32,000 million (up 38.5% year on year), and net income of ¥21,500 million (up 309.5% year on year). The large increase in net income is mainly attributable to the drop-off of the prior period's goodwill impairment loss of ¥14,729 million, and the underlying earnings growth rate should be evaluated on an operating income basis. The main drivers of the sales increase are expected to be expanded production capacity from the full-scale operation of the Yamagata plant and growth in domestic sales volume, but there are also several downside factors, including the annual drug price revisions, rising raw material costs, and the continued deterioration in sales of key overseas products due to the nitrosamine issue in the United States.

Growth Strategy

Establishment of the domestic 17.5 billion tablet production system and sustained growth through a tripolar global expansion across Japan, the U.S., and Europe

In October 2025, all equipment at the Third Solid Dosage Building of the Yamagata Plant was completed and full-scale operation began. Combined annual production capacity across the three plants will expand to 17.5 billion tablets from FY2026 (an increase of 2.5 billion tablets from the end of March 2024). This directly contributes to increased domestic sales volume and a strengthened stable supply system.

In January 2026, the company signed a basic agreement for strategic collaboration in pharmaceutical manufacturing with Otsuka Pharmaceutical. In April 2026, collaboration agreements were also reached with Adragos Pharma Kawagoe and Sanwa Kagaku Kenkyusho. The aim is to treat the patent-expired drug market as an integrated whole, securing manufacturing capacity and building a mutual backup system.

Sales grew in both European BtoB and BtoC businesses, achieving Overseas sales of ¥57,630 million (up 7.0% year on year) in FY2026 (ending March 2026). While sales of key U.S. products continue to be affected by the nitrosamine issue, growth in Europe has offset this decline. Deepening of group synergies (contract manufacturing, joint development) is also ongoing.

In FY2026 (ending March 2026), the company launched Japan's first product, Rivaruen® LA Patch (New Drug), as well as the authorized generic Prasugrel Tablets/OD Tablets. New products scheduled for supplementary listing in June 2026 comprise 7 active ingredients and 12 products. The company aims to improve profitability through sales mix improvement and higher unit prices.

In addition to the existing MES and LIMS, the company has newly introduced a QMS (Quality Management System). This strengthens compliance with PIC/S GMP and ICH guidelines, aiming to prevent human error and improve manufacturing and quality control. This is part of efforts to restore trust in the generic pharmaceuticals industry.

Last updated: July 19, 2026